Clinical characteristics of Danshen Ligustrazine injection in the treatment of coronary heart disease with hypertension-A real world study

扫码查看

原文链接

维普
万方数据

外文摘要：Objective: To explore the characteristics and rules of Danshen Ligustrazine Injection in the treatment of coronary heart disease with hypertension. Methods: From the information systems of 12 tertiary tier-one hospitals across the country, we extracted the medical data of the application of Danshen Ligustrazine Injection in the treatment of patients with coronary heart disease and hypertension. After normalization, the model was established by Apriori algorithm, and the association rules were analyzed by Clementine 12.0 software. Results: Most of the 1928 patients were between 75 and 90 years old (54.26％). There were more males than females, most with type 2 diabetes, cerebral infarction, etc. Each dose was more than 10 mL (52.78％). Aspirin enteric-coated tablets (67.63％), L-carnitine injection (58.77％), and atorvastatin calcium capsules (50.93％) were often used in combination with safflower yellow pigment (22.20％), Shexiang Baoxin Pill (16.55％), Suxiao Jiuxin Pill (15.09％); the most commonly used combination of western medicine was anticoagulant thrombolytic and antiplatelet drugs (85.84％), and the type of Chinese medicine was Huoxuehuayu (72.98％); The most common combination of two western medicines was L-carnitine injection+aspirin enteric-coated tablets, with a support of 41.9％; The most common combination of two Chinese and western medicines is western medicine·anti-anginal medicine + western medicine · anticoagulant thrombolytic and antiplatelet drugs with a support of 67.6％. Conclusion: Danshen Ligustrazine injection is mainly used in elderly patients with coronary heart disease and hypertension, with many comorbidities. The dosage standard needs to be optimized. The combination of drugs and guidelines should coordinate with each other, which provide clues for clinical diagnosis and treatment and optimization of medication.

外文关键词：

Real worldDanshen Ligustrazine InjectionCoronary heart diseaseHypertensionCombination medication

作者：

SUN Lin-xi、Gao Yang、XIE Yan-ming、Zhang Li-dan、XU Hong-yan、ZHUANG Yan

展开 >

作者单位：

Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China

Institute of Basic Medical Science of Xiyuan Hospital,Beijing 100091,China

School of Statistics,Renmin University of China,Beijing 100872,China

The PLA Navy General Hospital,Beijing 100048,China

展开 >

基金：

国家重点研发计划

项目编号：

2018YFC1707400

出版年：

2022

海南医科大学学报(英文版)

ISSN：

年,卷(期)：2022.28(17)

参考文献量22